Nektar Announces Positive Phase 2b Results for Rezpegaldesleukin in The Lancet

Key Facts

1Nektar Therapeutics announced the publication of peer-reviewed Phase 2b data from the REZOLVE-AD study in The Lancet.

2The study met all primary and key secondary endpoints for rezpegaldesleukin in moderate-to-severe atopic dermatitis.

In a move that underscores the ongoing innovation within the biotech sector, Nektar Therapeutics announced the publication of peer-reviewed Phase 2b data from its REZOLVE-AD study in The Lancet. According to reports, the study successfully met all primary and key secondary endpoints for rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis. This publication provides critical validation of the drug's efficacy and safety profile as it moves through the clinical pipeline.

The positive data supports the ongoing Phase 3 ZENITH AD program, with the peer-review process in a top-tier medical journal de-risking the drug's mechanism of action. Per analyst assessments, achieving endpoints such as EASI-75 and EASI-90 is a significant milestone for the small-cap company, although clinical development remains subject to substantial risks and regulatory hurdles typical of the industry.

Regarding market performance, current price levels for NKTR are unavailable in the latest data snapshot, suggesting investors should monitor qualitative momentum at the next market open. Looking ahead, the release of the FOMC Minutes on August 19, 2026, serves as a broader macro catalyst that could impact sentiment across high-growth sectors like biotechnology.

Sources:

prnewswire.com